Adial Pharmaceuticals Renames to Azora Therapeutics, Appoints New CEO
Adial Pharmaceuticals, Inc. has officially changed its corporate name to Azora Therapeutics, Inc. and appointed a new executive leadership team. Matthew Davidson, Ph.D. has been appointed President and Chief Executive Officer, succeeding Cary J. Claiborne. Celia Economides has been appointed Chief Financial Officer, succeeding Vinay Shah, and Julie Saiki, Ph.D. has been appointed Chief Strategy Officer. The company's common stock is expected to begin trading on Nasdaq under the new ticker symbol "AZR" on October 29, 2026. Azora Therapeutics is focused on advancing its lead asset, AT177, an oral, colon-targeted AhR agonist for ulcerative colitis, with a Phase 1 clinical trial expected in the first half of 2027. The company's current cash position is expected to fund operations into 2028.
Key Highlights
- Azora Therapeutics (formerly Adial Pharmaceuticals) appointed Matthew Davidson, Ph.D. as President and CEO.
- Celia Economides appointed as the new Chief Financial Officer.
- Julie Saiki, Ph.D. appointed as the new Chief Strategy Officer.
- The company announced its corporate name change to Azora Therapeutics, Inc.
- Azora Therapeutics expects to commence trading on Nasdaq under the new ticker symbol "AZR" on October 29, 2026.
- Phase 1 clinical trial initiation of AT177 is expected in the first half of 2027.
- Current cash and cash equivalents are expected to fund operational plans into 2028.
Price Impact
More from ADIL